Majestec-9, in post-Darzalex multiple myeloma, is the latest success.

JNJ-95566692 enters phase 1, with Qilu neck and neck.

The company will start three phase 3 trials of its G12D project this year.

But PFS data are lacking, and there are questions about first and second-line plans.

Three private biotechs enter clinical trials, one targeting KRAS.

But the company still has a lot to prove with ERAS-0015.